Bioavailability evaluation of a controlled-release dextromethorphan liquid.
A randomized, two-way, steady-state crossover study was performed in 24 healthy male volunteers to evaluate the bioavailability of a controlled-release (CR) dextromethorphan (DM) suspension. Only slow and intermediate DM metabolizers were allowed to participate in the study; determination of metabolizer status was performed before study enrollment. Each volunteer was administered 30 mg of an immediate-release (IR) DM solution qid or 60 mg DM as a CR suspension bid for two weeks, for a total daily dose of 120 mg. After a two-week washout period, the subjects were administered the alternate treatment. Blood samples were collected over a 12-hour dosing period on the last day of each treatment and analyzed for DM and its active metabolite, dextrorphan (DP). In addition, urine was collected over the 12-hour steady-state dosing interval and measured for DM and two metabolites. Pharmacokinetic determinations were made from plasma DM and DP data, and total urinary excretion was determined. All comparisons made between the two formulations indicated that the CR DM suspension was bioequivalent to the IR DM solution at steady state, while producing a prolonged release of the drug over time.
Woodworth
J R
JR
Pennwalt Pharmaceutical Division, Rochester, New York.
Dennis
S R
SR
Hinsvark
O N
ON
Amsel
L P
LP
Rotenberg
K S
KS
D000293:Adolescent; D000328:Adult; D001682:Biological Availability; D003692:Delayed-Action Preparations; D003915:Dextromethorphan / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007981:Levorphanol / Q000031:analogs & derivatives*; D008297:Male
D003692:Delayed-Action Preparations; D007981:Levorphanol; D003915:Dextromethorphan